• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Inspire Medical Systems Inc.

    12/2/25 4:27:55 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001454092
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    INSPIRE MEDICAL SYSTEMS INC.
    SEC File Number
    001-38468
    Address of Issuer
    5500 Wayzata Blvd., Suite 1600
    Golden Valley
    MINNESOTA
    55416
    Phone
    844-672-4357
    Name of Person for Whose Account the Securities are To Be Sold
    SHAWN T MCCORMICK
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1200151608.002905643412/02/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/17/2023Previously Exercised Stock OptionsIssuerCheckbox not checked120003/17/2023Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for SHAWN T MCCORMICK
    5500 Wayzata Blvd., Suite 1600
    Golden Valley � MN � 55416
    COMMON11/28/20252000254960.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/02/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/29/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Shawn T McCormick

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $INSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    12/2/2025$130.00Overweight → Equal-Weight
    Morgan Stanley
    11/26/2025$165.00Hold → Buy
    Truist
    11/25/2025$180.00Peer Perform → Outperform
    Wolfe Research
    11/24/2025Hold → Buy
    Stifel
    11/4/2025$90.00Equal Weight → Overweight
    Wells Fargo
    10/24/2025$85.00Buy → Hold
    Jefferies
    9/22/2025$89.00Buy → Neutral
    UBS
    9/2/2025$150.00Outperform
    Evercore ISI
    More analyst ratings

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    1/24/24 4:32:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Inspire Medical Systems from Overweight to Equal-Weight and set a new price target of $130.00

    12/2/25 8:18:26 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems upgraded by Truist with a new price target

    Truist upgraded Inspire Medical Systems from Hold to Buy and set a new price target of $165.00

    11/26/25 8:30:25 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Inspire Medical Systems from Peer Perform to Outperform and set a new price target of $180.00

    11/25/25 8:32:37 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspire Medical Systems, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

    MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025. Inspire is scheduled to present at 11:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://inves

    11/18/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Third Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2025. Recent Business Highlights Generated revenue of $224.5 million in the third quarter of 2025, a 10% increase over the same quarter last yearAchieved gross margin of 85.8% in the third quarter of 2025Net income was $9.9 million in the third quarter of 2025. Adjusted net income was $11.2 millionIncome per share was $0.34 in the third quarter

    11/3/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Present at the 2025 UBS Global Healthcare Conference

    MINNEAPOLIS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 2025 UBS Global Healthcare Conference on Monday, November 10, 2025. Inspire is scheduled to present at 11:45 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspi

    10/27/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    SEC Filings

    View All

    SEC Form 144 filed by Inspire Medical Systems Inc.

    144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

    12/2/25 4:27:55 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Inspire Medical Systems Inc.

    144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/28/25 1:16:38 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems Inc. filed SEC Form 8-K: Other Events

    8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

    11/17/25 4:36:42 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccormick Shawn sold $254,960 worth of shares (2,000 units at $127.48), decreasing direct ownership by 7% to 26,046 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    12/1/25 5:56:40 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Melenikiotou Georgia was granted 229 shares, increasing direct ownership by 6% to 3,986 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    10/16/25 4:16:07 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

    Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

    12/5/24 12:12:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/4/24 2:09:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    2/13/24 5:06:20 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Financials

    Live finance-specific insights

    View All

    Inspire Medical Systems, Inc. Announces Third Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2025. Recent Business Highlights Generated revenue of $224.5 million in the third quarter of 2025, a 10% increase over the same quarter last yearAchieved gross margin of 85.8% in the third quarter of 2025Net income was $9.9 million in the third quarter of 2025. Adjusted net income was $11.2 millionIncome per share was $0.34 in the third quarter

    11/3/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025

    MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi

    10/6/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last yearAchieved gross margin of 84.0% in the second quarter of 2025Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 millionLoss per share was $0.12 in the second quarter of

    8/4/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care